Lipoprotein metabolism & CV risk: a long road from understanding to treatment

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

What we can learn from registry data to improve lipid goal attainment
What we can learn from registry data to improve lipid goal attainment
Hyperlipidemia
What we can learn from registry data to improve lipid goal attainment
- Kausik Ray, MBChB, MD, MPhil
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
MinuteCE®
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
0.75 program credits
- Julia Brandts, MD
0.75 program credits